Genomic alterations in pancreatic cancer and their relevance to therapy.
Pancreatic cancer is a highly lethal cancer type, for which there are few viable therapeutic options. But, with the advance of sequencing technologies for global genomic analysis, the landscape of genomic alterations in pancreatic cancer is becoming increasingly well understood. In this review, we summarize current knowledge of genomic alterations in 12 core signaling pathways or cellular processes in pancreatic ductal adenocarcinoma, which is the most common type of malignancy in the pancreas, including four commonly mutated genes and many other genes that are mutated at low frequencies. We also describe the potential implications of these genomic alterations for development of novel therapeutic approaches in the context of personalized medicine.
Erina Takai, Shinichi Yachida, Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Erina
E
Takai
Erina Takai, Shinichi Yachida, Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Shinichi
S
Yachida
Genomic alterations; Pancreatic cancer; Personalized medicine; Signaling pathways; Therapeutic targets